Global Migraine Therapeutics Market 2018-2023: Increasing Prevalence of Migraines is Driving Growth (8.4% CAGR) - ResearchAndMarkets.com

September 6, 2018

DUBLIN--(BUSINESS WIRE)--Sep 6, 2018--The “Global Migraine Therapeutics Market - Segmented by Treatment, Therapeutics and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The global migraine therapeutics market is expected to grow at a CAGR of 8.4% over the forecast period 2018-2023.

Increasing Prevalence of Migraines

Due to the high unmet needs the major pharmaceutical companies have initiated several R&D programs to launch new molecules and are trying to increase the market access of the generic formulations across the globe.Moreover, the growing awareness of migraine therapeutics and improvement in accurate diagnosis of the condition are expected to favor the market expansion over the next few years.Notable HighlightsLack of Proper Diagnosis & Undiagnosed CasesAsia-Pacific to Emerge as the Fastest Growing Region

Key Development in the Market

A new type of medication for migraine headaches is currently being reviewed by the FDA, and if approved may provide safe, long-lasting relief for many by blocking the activation of a molecule involved in the pain process.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

Companies Mentioned

AllerganAmirallAstraZenecaGlaxoSmithKlineMerckOptiNosePfizerRedHill BiopharmaRevance TherapeuticsTeva

For more information about this report visit https://www.researchandmarkets.com/research/2669qs/global_migraine?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005481/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs,Analgesics



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/06/2018 08:38 AM/DISC: 09/06/2018 08:38 AM


Update hourly